Trials / Completed
CompletedNCT00288561
Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration
Open-Label, Multicenter, Phase II Study Assessing the Safety of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Occult or Predominately Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (ARMD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
Ranibizumab is derived from a murine monoclonal anti- vascular endothelial growth factor (VEGF) antibody and can penetrate through the many retinal cell layers following intravitreal injection. The present study is directed towards the assessment of ranibizumab administered on the same day in combination with verteporfin in patients with subfoveal CNV secondary to ARMD
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ranibizumab |
Timeline
- Start date
- 2004-11-01
- Completion
- 2007-07-01
- First posted
- 2006-02-08
- Last updated
- 2008-06-19
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00288561. Inclusion in this directory is not an endorsement.